TY - JOUR
T1 - Novel doxorubicin loaded PEGylated cuprous telluride nanocrystals for combined photothermal-chemo cancer treatment
AU - Wang, Xianwen
AU - Ma, Yan
AU - Chen, Huajian
AU - Wu, Xiaoyi
AU - Qian, Haisheng
AU - Yang, Xianzhu
AU - Zha, Zhengbao
N1 - Funding Information:
This work was financially supported by the National Natural Science Foundation of China (No. 81501590; No. 31500808; No. 21471043), the Anhui Provincial Natural Science Foundation (No. 1608085MH188), the Fundamental Research Funds for the Central Universities (No. 2015HGCH0006; No. JZ2015HGBZ0103).
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Recently, combined photothermal-chemo therapy has attracted great attention due to its enhanced anti-tumor efficiency via synergistic effects. Herein, PEGylated cuprous telluride nanocrystals (PEGylated Cu2Te NCs) were developed as novel drug nanocarriers for combined photothermal-chemo treatment of cancer cells. PEGylated Cu2Te NCs were fabricated through a simple two-step process, comprised of hot injection and thin-film hydration. The as-prepared PEGylated Cu2Te NCs (average diameter of 5.21 ± 1.05 nm) showed a noticeable photothermal conversion efficiency of 33.1% and good capacity to load hydrophobic anti-cancer drug. Due to the protonated amine group at low pH, the doxorubicin (DOX)-loaded PEGylated Cu2Te NCs (PEGylated Cu2Te-DOX NCs) exhibited an acidic pH promoted drug release profile. Moreover, a three-parameter model, which considers the effects of drug-carrier interactions on the initial burst release and the sustained release of drug from micro- and nano-sized carriers, was used to gain insight into how pH and laser irradiation affect drug release from PEGylated Cu2Te-DOX NCs. Based on the results from in vitro cell study, PEGylated Cu2Te-DOX NCs revealed remarkably photothermal-chemo synergistic effect to HeLa cells, attributed to both the PEGylated Cu2Te NCs mediated photothermal ablation and enhanced cellular uptake of the drug. Thus, our results encourage the usage of Cu2Te-DOX drug nanocarriers for enhanced treatment of cancer cells by combined photothermal-chemo therapy.
AB - Recently, combined photothermal-chemo therapy has attracted great attention due to its enhanced anti-tumor efficiency via synergistic effects. Herein, PEGylated cuprous telluride nanocrystals (PEGylated Cu2Te NCs) were developed as novel drug nanocarriers for combined photothermal-chemo treatment of cancer cells. PEGylated Cu2Te NCs were fabricated through a simple two-step process, comprised of hot injection and thin-film hydration. The as-prepared PEGylated Cu2Te NCs (average diameter of 5.21 ± 1.05 nm) showed a noticeable photothermal conversion efficiency of 33.1% and good capacity to load hydrophobic anti-cancer drug. Due to the protonated amine group at low pH, the doxorubicin (DOX)-loaded PEGylated Cu2Te NCs (PEGylated Cu2Te-DOX NCs) exhibited an acidic pH promoted drug release profile. Moreover, a three-parameter model, which considers the effects of drug-carrier interactions on the initial burst release and the sustained release of drug from micro- and nano-sized carriers, was used to gain insight into how pH and laser irradiation affect drug release from PEGylated Cu2Te-DOX NCs. Based on the results from in vitro cell study, PEGylated Cu2Te-DOX NCs revealed remarkably photothermal-chemo synergistic effect to HeLa cells, attributed to both the PEGylated Cu2Te NCs mediated photothermal ablation and enhanced cellular uptake of the drug. Thus, our results encourage the usage of Cu2Te-DOX drug nanocarriers for enhanced treatment of cancer cells by combined photothermal-chemo therapy.
KW - Anti-tumor treatment
KW - Chemotherapy
KW - Cuprous telluride
KW - Drug nanocarriers
KW - Photothermal therapy
UR - http://www.scopus.com/inward/record.url?scp=85011878207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011878207&partnerID=8YFLogxK
U2 - 10.1016/j.colsurfb.2017.02.002
DO - 10.1016/j.colsurfb.2017.02.002
M3 - Article
C2 - 28187379
AN - SCOPUS:85011878207
SN - 0927-7765
VL - 152
SP - 449
EP - 458
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
ER -